Inhibition of Targeted Bacterial Growth Using MazF‐Expressing Phagemids: A Novel Therapeutic Approach Based on Endoribonuclease Toxin Molecules
Microbiology and Immunology · 2026
DOI: 10.1111/1348-0421.70046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2026. Verfasst von Hana Hasegawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science and Medical Bioscience, Waseda University, Shinjuku-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Endoribonucleases, Escherichia coli, Bacterial Toxins, DNA-Binding Proteins. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Grant/Award Number: JP21K15439; Takahashi Industrial and Economic Research Foundation, Grant/Award Number: 11-003-3….
Abstract (Originalsprache)
The extensive and indiscriminate use of antibiotics, which are intended to halt bacterial growth or eliminate them, has unintentionally given rise to antimicrobial resistance (AMR), which is a critical threat to global health. In the pursuit of alternative solutions, researchers have focused on type II toxin–antitoxin systems prevalent within the bacterial domain. One such promising example is the MazF toxin, which has been demonstrated to cleave RNA at specific sequences. MazF toxins are now recognized as present in a diverse range of bacterial species and exhibit varying cleavage sequence specificities. This diversity offers the potential for controlling bacterial growth by silencing the expression of hundreds of essential genes. In this study, a preliminary screening of five MazF homologs from distinct taxonomic groups was conducted to identify a MazF candidate that can effectively suppress bacterial proliferation. MazFne1, an endoribonuclease toxin originating from Nitrosomonas europaea that specifically targets UGG sequences, emerged as a promising candidate. Building upon this discovery, a phagemid system was engineered to deliver mazFne1 and express it in two distinct Escherichia coli strains. This approach successfully inhibited E. coli growth, suggesting a potential strategy for developing therapeutic interventions to combat antibiotic‐resistant bacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Science and Medical Bioscience, Waseda University, Shinjuku-ku, Tokyo, Japan.
- Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Sapporo, Hokkaido, Japan.
- Phage Therapy Institute, Comprehensive Research Organization, Waseda University, Shinjuku-ku, Tokyo, Japan.
- Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan.
ORCID-Profile: Naohiro Noda
Förderung
- Japan Society for the Promotion of Science, Grant/Award Number: JP21K15439; Takahashi Industrial and Economic Research Foundation, Grant/Award Number: 11-003-3…
Zitieren
APA
Hasegawa, H., Miyamoto, T., Isshiki, R., Kaneko, T., Takasugi, K., Noda, N., & Tsuneda, S. (2026). Inhibition of Targeted Bacterial Growth Using MazF‐Expressing Phagemids: A Novel Therapeutic Approach Based on Endoribonuclease Toxin Molecules. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.70046
Vancouver
Hasegawa H, Miyamoto T, Isshiki R, Kaneko T, Takasugi K, Noda N, et al. Inhibition of Targeted Bacterial Growth Using MazF‐Expressing Phagemids: A Novel Therapeutic Approach Based on Endoribonuclease Toxin Molecules. Microbiology and Immunology. 2026. doi:10.1111/1348-0421.70046
BibTeX
@article{Hasegawa2026,
author = {Hasegawa, Hana and Miyamoto, Tatsuki and Isshiki, Rino and Kaneko, Tomoyoshi and Takasugi, Kenichi and Noda, Naohiro and Tsuneda, Satoshi},
title = {Inhibition of Targeted Bacterial Growth Using MazF‐Expressing Phagemids: A Novel Therapeutic Approach Based on Endoribonuclease Toxin Molecules},
journal = {Microbiology and Immunology},
year = {2026},
doi = {10.1111/1348-0421.70046}
}
EUVIMED